secwatch.observer — SEC 8-K summary
======================================

Issuer:     EAGLE PHARMACEUTICALS, INC. (—)
CIK:        0000827871
Form:       8-K
Filed at:   2024-04-12T23:59:59+00:00
Accession:  0001104659-24-046776
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eagle Pharma faces potential Nasdaq delisting after 10-K delay; may miss extension deadline
--------------------------------------------------------------------------------

- Received Nasdaq notice on April 8 for failure to timely file FY 2023 Form 10-K; prior Q3 10-Q also late.
- Company previously granted extension to May 13, 2024 to regain compliance; must submit updated plan by April 23.
- Company believes it is unlikely to file Form 10-Q or 10-K by May 13 extension deadline.
- Nasdaq may accelerate delisting; company could request hearing to stay suspension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/827871/000110465924046776/0001104659-24-046776-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/827871/000110465924046776/tm2411717d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-046776

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer